These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34167483)

  • 1. Multiple sclerosis projection in Tehran, Iran using Bayesian structural time series.
    Amini P; Almasi-Hashiani A; Sahraian MA; Najafi M; Eskandarieh S
    BMC Neurol; 2021 Jun; 21(1):235. PubMed ID: 34167483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of an increased prevalence of multiple sclerosis: a population-based study of Tehran registry during 1999-2018.
    Almasi-Hashiani A; Sahraian MA; Eskandarieh S
    BMC Neurol; 2020 May; 20(1):169. PubMed ID: 32359352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing prevalence of familial recurrence of multiple sclerosis in Iran: a population based study of Tehran registry 1999-2015.
    Eskandarieh S; Allahabadi NS; Sadeghi M; Sahraian MA
    BMC Neurol; 2018 Feb; 18(1):15. PubMed ID: 29415659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of familial multiple sclerosis in Iran: a national registry-based study.
    Salehi Z; Almasi-Hashiani A; Sahraian MA; Ashtari F; Baghbanian SM; Razazian N; Moghadasi AN; Bayati A; Azimi AR; Beladimoghadam N; Harirchian MH; Poursadeghfard M; Navardi S; Shirkoohi R; Heidari H; Ghaffari M; Eskandarieh S
    BMC Neurol; 2022 Mar; 22(1):76. PubMed ID: 35248009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of familial multiple sclerosis: A population-based study in Tehran during 1999-2018.
    Salehi Z; Almasi-Hashiani A; Sahraian MA; Eskandarieh S
    Mult Scler Relat Disord; 2020 Aug; 43():102178. PubMed ID: 32417663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence and prevalence of crude and familial multiple sclerosis in Tehran, Iran in 2021.
    Ezabadi SG; Ayoubi S; Sahraian MA; Omrani MA; Eskandarieh S
    Neurol Sci; 2023 Dec; 44(12):4517-4518. PubMed ID: 37642789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study.
    Elhami SR; Mohammad K; Sahraian MA; Eftekhar H
    Neuroepidemiology; 2011; 36(3):141-7. PubMed ID: 21508646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of familial multiple sclerosis and its comparison to sporadic form in Markazi Province, Iran.
    Faraji F; Mohaghegh P; Talaie A
    Mult Scler Relat Disord; 2022 Dec; 68():104231. PubMed ID: 36270251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple Sclerosis in Tehran: Rising Prevalence alongside Stabilizing Incidence - True Increase or Enhanced Diagnosis?
    Mohebi F; Eskandarieh S; Mansournia MA; Mohajer B; Sahraian MA
    Arch Iran Med; 2019 Aug; 22(8):429-434. PubMed ID: 31679345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal Incidence and Prevalence Trends of Multiple Sclerosis in Markazi Province, Iran.
    Faraji F; Ahmadi F; Mohaghegh P; Talaie A
    Mult Scler Relat Disord; 2022 Apr; 60():103691. PubMed ID: 35217485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric multiple sclerosis and its familial recurrence: A population based study (1999-2017).
    Eskandarieh S; Sahraiain MA; Molazadeh N; Moghadasi AN
    Mult Scler Relat Disord; 2019 Nov; 36():101377. PubMed ID: 31473489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing epidemiology and baseline characteristic of multiple sclerosis and neuromyelitis optica: A case-control study.
    Eskandarieh S; Nedjat S; Abdollahpour I; Moghadasi AN; Azimi AR; Sahraian MA
    Mult Scler Relat Disord; 2017 Feb; 12():39-43. PubMed ID: 28283104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis in Isfahan, Iran.
    Saadatnia M; Etemadifar M; Maghzi AH
    Int Rev Neurobiol; 2007; 79():357-75. PubMed ID: 17531850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran.
    Etemadifar M; Maghzi AH
    Mult Scler; 2011 Aug; 17(8):1022-7. PubMed ID: 21459809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time.
    Sahraian MA; Khorramnia S; Ebrahim MM; Moinfar Z; Lotfi J; Pakdaman H
    Eur Neurol; 2010; 64(6):331-6. PubMed ID: 21071949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal trends of incidence and prevalence of multiple sclerosis in Razavi Khorasan Province, Northeast Iran.
    Sarmadi M; Saravani H; Azizi O; Najafi F; Hadei M; Momeni J; Bazrafshan E
    Neurol Sci; 2022 Jan; 43(1):583-591. PubMed ID: 33939041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion of interferon beta in Iran and its utilization in Tehran.
    Palesh M; Jonsson PM; Jamshidi H; Wettermark B; Tomson G; Fredrikson S
    Pharmacoepidemiol Drug Saf; 2008 Sep; 17(9):934-41. PubMed ID: 18509835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the multiple sclerosis (MS) map need to change again? An update of MS prevalence in Mazandaran province of Iran in 2018.
    Baghbanian SM; Cheraghmakani H; HabibiSaravi R; Azar A; Ghasemihamedani F
    BMC Neurol; 2020 Feb; 20(1):52. PubMed ID: 32050931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-trend analysis and developing a forecasting model for the prevalence of multiple sclerosis in Kohgiluyeh and Boyer-Ahmad Province, southwest of Iran.
    Mousavizadeh A; Dastoorpoor M; Naimi E; Dohrabpour K
    Public Health; 2018 Jan; 154():14-23. PubMed ID: 29128732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis incidence temporal trend in the Northeast of Iran: Using the Empirical Bayesian method.
    Taghizadeh-Diva SE; Khosravi A; Zolfaghari S; Hosseinzadeh A
    Mult Scler Relat Disord; 2023 Feb; 70():104469. PubMed ID: 36587485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.